About Us

3차원 세포배양 플랫폼 항암제 감수성 및 효능/독성 검사 전문 기업

3차원 세포배양 플랫폼 항암제 감수성 및 효능/독성 검사
전문 기업

논문 2022, International Journal of Molecular Sciences, Patient-Derived Tum…

페이지 정보

작성자 MBD
댓글 0건 조회 2,659회 작성일 22-06-14 08:56


 An obstacle to effective uniform treatment of glioblastoma, especially at recurrence, is genetic and
cellular intertumoral heterogeneity. Hence, personalized strategies are necessary, as are means to stratify
potential targeted therapies in a clinically relevant timeframe. Functional profiling of drug candidates against
patient-derived glioblastoma organoids (PD-GBO) holds promise as an empirical method to preclinically
discover potentially effective treatments of individual tumors. Here, we describe our establishment of a PDGBO-based functional profiling platform and the results of its application to four patient tumors. We show
that our PD-GBO model system preserves key features of individual patient glioblastomas in vivo. As proof
of concept, we tested a panel of 41 FDA-approved drugs and were able to identify potential treatment options
for three out of four patients; the turnaround from tumor resection to discovery of treatment option was 13, 14,
and 15 days, respectively. These results demonstrate that this approach is a complement and, potentially, an
alternative to current molecular profiling efforts in the pursuit of effective personalized treatment discovery
in a clinically relevant time period. Furthermore, these results warrant the use of PD-GBO platforms for
preclinical identification of new drugs against defined morphological glioblastoma features.